AiCuris

AiCuris is a clinical-stage biotech company developing targeted antiviral therapies, with a lead asset, pritelivir, demonstrating positive Phase 3 results for refractory herpes simplex virus (HSV) in immunocompromised patients. The company has built a robust pipeline targeting significant unmet needs in severe infectious diseases and is led by an experienced management team with deep virology and commercial expertise. In February 2026, the company entered into an agreement to be acquired by Asahi Kasei, which is expected to accelerate its growth and global reach.

Small molecule antiviral drug discovery platform with deep virology expertise, focusing on novel mechanisms of action to overcome viral resistance, particularly for herpesviruses and other infections in immunocompromised patients.

Competition includes generic nucleoside analogs (acyclovir, valacyclovir) and newer agents like maribavir for CMV. However, pritelivir's novel mechanism targets a clear unmet need in resistant/refractory HSV, where there are few effective alternatives, giving it a potential best-in-class position in a defined niche.